UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 2009
IMARX THERAPEUTICS, INC.
(Exact name
of registrant as specified in its charter)
| Delaware | 001-33043 | 86-0974730 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 12277 134th Court NE, Suite 202, Redmond, WA |
98052 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (425) 821-5501
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 8.01 Other Events
On February 19, 2009, ImaRx Therapeutics, Inc. issued the press release attached to this report as Exhibit 99.1. The content of the press release is incorporated herein by this reference.
ITEM 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 |
Press Release issued by ImaRx Therapeutics, Inc. on February 19, 2009. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 20, 2009
IMARX THERAPEUTICS, INC.
/s/ BRADFORD A.
ZAKES
By: Bradford A. Zakes
President and Chief Executive Officer
EXHIBIT INDEX
|
Exhibit Number
|
Description | |
|
|
||
|
99.1
|
Press Release issued by ImaRx Therapeutics, Inc. on February 19, 2009. |